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Purpose: One among seven women will present with breast cancer for which major 
therapeutic advances led to a significant increase in survival and cure rates. During or 
after cancer treatment, severe complications may occur requiring admission in intensive 
care unit (ICU). Intensivists could be reluctant for accepting cancer patients in the ICU, 
and there are very few data about causes of admission and prognosis of patients with 
breast cancer admitted in the ICU for an acute complication. Our study seeks to deter-
mine, in a population of patients with breast cancer, the main causes for ICU admission 
and the predictors of death during hospital stay and prognostic factors for survival after 
hospital discharge.
Methods: This retrospective study includes all unplanned ICU admissions of patients 
with breast cancer in a cancer hospital from January 1, 2009 to December 31, 2014. 
To search for predictive factors of death during hospitalization, Mann–Whitney or Fisher 
Exact (or chi-square) tests were used for continuous variables or categorical variables, 
respectively. A logistic regression model was applied for multivariate analysis. Multivariate 
analysis of prognostic factors for survival after hospital discharge was performed with a 
Cox’s proportional hazards model.
results: Of 1586 ICU admissions during the study period, 282 (18%) concerned breast 
cancer of which 175 met the inclusion criteria. The main causes of admission were of 
cardiovascular (26%), respiratory (19%), neurologic (19%), or infectious (14%) origin. 
ICU death rate was 15% and, overall, 28% of the patients died during hospitalization. 
The median survival time after hospitalization was 12.8 months (95% CI: 8.2–20.7). 
Independent predictors of death during hospitalization were the sequential organ 
failure assessment (SOFA) score (OR 1.36, 95% CI 1.15–1.60), high GPT values (OR 
3.70, 95% CI: 1.52–9.03), and cardiovascular disease (OR 0.23, 95% CI: 0.06–0.86). 
Independent predictors of death after hospital discharge were metastatic disease (HR 
7.90, 95% CI 3.69–16.92), high GOT value (HR 3.22 95% CI: 1.93–5.36), simplified 
acute physiology score (SAPS) (HR 1.95 95% CI: 1.21–3.16), and therapeutic limita-
tions during the first 24 h after ICU admission (HR 8.52 95% CI: 3.66–19.87).
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inTrODUcTiOn
In Europe, approximately one in seven patients admitted to an 
intensive care unit (ICU) are presenting with a cancer, mainly 
solid tumors (1). Reasons for admitting cancer patients in the 
ICU are multiple, including complications due to cancer or its 
treatment as well as other diseases unrelated to the neoplastic 
disease. The majority of publications on cancer patients in ICU 
are concerning populations with mixed types of cancers patients 
with hematological malignancies or lung cancer (2, 3). Survival 
of cancer patients admitted to the ICU is influenced by the 
physiological disturbances caused by the complications leading 
to ICU admission. Cancer characteristics recovered all their 
importance for further prognosis only after hospital discharge. In 
this setting, a discussion between the intensivist and the treating 
oncologist is of particular importance. Both have to integrate the 
therapeutic option, and the possibility of cancer control as well as 
the prognosis linked to the acute complication before admitting 
in the ICU and/or determining the potential limits of the critical 
management.
Breast cancer is the leading cause of cancer in women with 
an incidence of 110/100,000 in Belgium in 2013 (4). Meaningful 
improvement in survival and cure rates are been obtained with 
newer systemic therapies. Even for metastatic breast cancer, which 
is unlikely to be cured, median overall survival is reaching 2 years, 
with a range from a few months to many years. These women can 
thus have complications related or not to the tumors and its anti-
cancer treatment (febrile neutropenia and septic shock, cardiac 
failure, respiratory failure, new adverse events from innovative 
biological therapies…) that worsens the prognosis but can be 
improved with intensive care support.
There are few data published about causes of admission and 
prognosis of patients with breast cancer admitted in the ICU 
for an acute complication. Having a better knowledge of the 
diseases leading to ICU admission and of the prognosis of such 
patients might help in triage decision as well for intensivists 
and oncologists. A retrospective study, which aimed to validate 
the prognostic value of the APACHE II score in 66 patients 
with breast cancer identified respiratory failure as the primary 
reason for ICU admission (29%), pericardial effusion (23%), and 
cardiac arrhythmias (12%) being in second and third positions 
(5). Prognostic factors for hospital mortality were the APACHE 
II score, presence and number of metastases, reason of ICU 
admission and length of ICU stay. Another small study, including 
patients with gynecological (ovarian, endometrial, and cervical) 
and 11 breast cancer, identified sepsis (95%), and respiratory 
failure (37%) as the main reasons for ICU admission. The ICU 
mortality rate was 31%, overall mortality of the patients during 
hospitalization was 58%, and 6-month mortality rate was 68% (6).
The aim of the present study was to determine the main 
causes of ICU admission in patients with breast cancer treated 
in an academic cancer center. We also sought to identify pre-
dictors of death during hospitalization and prognostic factors 
for survival after hospital discharge in order to help further 
selection of breast cancer patients, which may benefit from ICU 
admission.
PaTienTs anD MeThODs
This retrospective study is based on the medical records of 
patients consequently admitted to the ICU of an academic 
cancer center, between January 1, 2009 and December 31, 
2014. In our oncological center, ICU admission occurred after 
extensive discussion between the intensivist and the oncolo-
gist who take care of the patient, based on the oncological 
therapeutic plan, the ICU indications and the patient’s wish. 
Inclusion criteria were all breast cancer patients admitted in 
the ICU for an acute, potentially life-threatening, complica-
tion (respiratory failure, shock, arrhythmias…). Patients with 
planned admissions were excluded. Planned admissions are 
defined as monitoring of a treatment at risk (allergic reac-
tion, arrhythmias…) or postoperative monitoring of planned 
surgery. We also excluded patients with another active cancer. 
This study was approved by the local ethical committee of the 
Institute Jules Bordet on October 16, 2014.
For each admission, the following data were retrospectively 
retrieved from the computerized charts:
 – Age, sex, comorbidities according to the Charlson’s score 
(giving one point each: myocardial infarct, congestive heart 
failure, peripheral vascular disease, dementia, cerebrovascu-
lar disease, chronic lung disease, connective tissue disease, 
ulcer, chronic liver disease, and diabetes; two points each: 
hemiplegia, moderate or severe kidney disease, diabetes with 
end organ damage, tumor, leukemia, and lymphoma; three 
points each: moderate or severe liver disease; six points each: 
malignant tumor, metastasis, and AIDS).
 – Date of first cancer diagnosis, cancer stage (metastatic or not).
 – Anticancer treatment (with all systemic anticancer therapy – 
chemotherapy or targeted therapy in the 30  days before 
admission to the ICU).
 – Cancer phase according to the Australian classification (7): 
diagnostic phase when the patient is under work-up for newly 
diagnosed neoplasia; curative phase when a curative treatment 
is started or when the patient is cured or in complete remis-
sion; control phase when the therapeutic project can lead to 
a temporary remission with improved survival but without 
possibility of cure; pivotal phase when a disease-oriented 
conclusion: Independent predictors of death during hospitalization were related to 
the acute complications (SOFA score, GPT level and cardiovascular-related admission) 
while cancer parameters retained their prognostic significance for survival after hospital 
discharge (metastatic disease, therapeutic limitations).
Keywords: breast cancer, intensive care, survival
TaBle 1 | characteristics of breast cancer patients admitted in the icU.
Patient’s characteristics N %
Womena 159 100
Median agea (min–max) 57 (27–91)
Metastatic stageb 134 77
Cancer statusb
•	 Induction treatment 15 9
•	 Complete remission 26 15
•	 Partial remission 1 <1
•	 Stable 31 18
•	 Progression 102 58
Cancer phaseb
•	 Diagnostic 4 2
•	 Curative 42 24
•	 Control 109 62
•	 Pivotal 19 11
•	 Palliative 1 <1
Anticancer treatment ongoing 30 days before ICUb 75 43
•	 Chemotherapy 67 38
•	 Targeted therapy 7 4
•	 Missing data 1 <1
Median Glasgow scoreb (min–max) 15 (5–15)
Median Charlson scoreb (min–max) 8 (3–15)
Median SAPS 2 scoreb (min–max) 34 (13–81)
Median SOFA scoreb (min–max) 2 (0–11)
Neutropeniab 14 8
aN = 159 patients.
bN = 175 admissions.
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treatment is no longer available requiring a switch to palliative 
care; palliative phase when only comfort care can be proposed.
 – Cancer status has been divided in five categories: induction 
therapy, complete remission (defined as complete disap-
pearance of all manifestations of disease found on physical 
examination and radiologic study) under treatment or with-
out active therapy, partial remission (defined as 50% or greater 
reduction in the measurable parameters of tumor growth as 
may be found on physical examination and radiologic study), 
stable disease, or progressive disease according to the last 
disease work-up.
 – Date and reason for ICU admission; when multiple reasons of 
ICU admission being found, only the initial event responsible 
for the physiological disturbances was considered.
 – Biological data: transaminases (GOT, GPT), alkaline phos-
phatases (PAL), lactate dehydrogenase (LDH), C-reactive 
protein (CRP), lactate, hemoglobin levels, neutrophils, and 
lymphocyte count.
 – Treatment limitations distinguishing between preexisting 
limitations, limitations occurring during the first 24  h after 
ICU admission and limitations occurring after 24 h in the ICU. 
We determined the reasons for these limitations: neoplasia, 
multifactorial (including a neoplastic cause, treatment com-
plication, and/or infectious complication), and other reason.
 – Life supporting techniques used in the ICU: invasive and/
or non-invasive ventilation, vasoactive amines, dialysis, and 
cardiopulmonary resuscitation.
 – Length of ICU and hospital stay, date, and cause of death (for 
the surviving patients, the date of last follow-up was used).
statistical analyses
We assessed two outcomes: (1) hospital death (binary out-
come), i.e., alive at the end of hospitalization vs. died during 
the hospitalization (in the ICU or in another hospital unit) and 
(2) time to death after hospital discharge in the patients alive at 
the end of hospitalization (time to event outcome). In patients 
with more than one ICU admission, we considered only the first 
admission.
To assess differences between patients who died during hos-
pitalization and those alive at end of hospitalization, the Mann–
Whitney test was used for continuous variables and the Fisher 
Exact or chi-square test for categorical variables. Multivariate 
analysis for predictors of in-hospital death was done with a 
logistic regression model.
To assess prognostic factors for survival after hospital dis-
charge, we calculated hazard ratios (HRs) using Cox’s propor-
tional hazards model. Continuous variables were dichotomized 
using the median in all ICU admitted patients.
For both the multivariate model of hospital mortality (first 
outcome variable) as the multivariate model for survival after 
hospital discharge (second outcome variable), we considered only 
variables with a univariate p-value <0.20 as possible predictor 
for the respective outcome, and performed stepwise variable 
selection.
All statistical analyses were performed using SAS 9.3. All 
reported p-values are two-tailed and a p-value <0.05 was consid-
ered as statistically significant.
resUlTs
Between January 1, 2009 and December 31, 2014, there were 1586 
ICU admissions of whom 282 (18%) concerned patients with 
breast cancer. Of those 282 patients, 107 were ineligible for the 
study: therapeutic monitoring (n =  46), planned postoperative 
monitoring (n = 36), more than one active cancer at the time of 
admission (n = 19), and other causes (n = 6). Due to multiple 
admissions in the same patient, 159 patients accounted for the 
175 admissions. All admissions were considered for the descrip-
tion of causes of ICU admission but only the first stay in the ICU 
was considered for hospital mortality and survival after discharge 
analyses.
Table 1 shows the main patients’ characteristics. Table 2 shows 
the principal reason for ICU admission. They were in decreas-
ing frequencies from cardiovascular (26%), respiratory (19%), 
neurologic (19%), metabolic (10%), infectious (8%), renal (8%), 
digestive (5%), and hemodynamic (5%) origins. Table  3 sum-
marizes the therapeutic limitations decided for 44 admissions. 
These limitations were mostly due to the cancer evolution found 
after ICU admission or during ICU stay.
Life supporting techniques were used during 105 admissions: 
56 non-invasive ventilations, 20 vasoactive amines, 16 invasive 
ventilations, 10 continuous venovenous hemodiafiltration 
(CVVHDF), and 3 cardiopulmonary resuscitations.
Forty-four (28%) patients died during the hospital stay 
mainly for reasons related to neoplasia (17%). Twenty-four 
(15%) patients died in the ICU, and 20 patients after ICU 
discharge during the hospital stay. Table  4 shows the results 
of the univariate analyses for hospital mortality. The following 
TaBle 3 | life support techniques limitations for breast cancer patients 
admitted in the icU.
life support techniques, limitations, and causes N: 175 %
Limitations 44 25
•	 Limitations at ICU admission or during the first 24 h 18 10
•	 Limitations beyond 24 h 26 15
Causes of limitations
•	 Neoplasia 34 19
•	 Multifactorial 5 3
•	 Others 4 2
•	 Unknown by missing data in the chart 1 <1
TaBle 2 | causes of admission in the icU of breast cancer patients.
causes of admission N %
Cardiovascular 45 26
•	 Cardiac failure 12 7
•	 Thrombosis and pulmonary embolism 10 6
•	 Syncope 8 5
•	 Arrhythmia 8 5
•	 Pericarditis 4 2
•	 Myocardial ischemia 1 <1
•	 Cardiac arrest 1 <1
•	 Hypertensive emergency 1 <1
Respiratory 34 19
•	 Pneumonia 10 6
•	 Severe respiratory distress of multifactorial causes 9 5
•	 Pleural effusion 8 5
•	 Chronic obstructive pulmonary disease exacerbation 3 2
•	 Pneumothorax 2 1
•	 Severe asthma 1 <1
•	 Hemoptysis 1 <1
Neurological 33 19
•	 Seizures 14 8
•	 Coma/impaired alertness 5 3
•	 Intracranial hypertension 5 3
•	 Cerebral hemorrhage 4 2
•	 Stroke 3 2
•	 Paralytic syndrome 2 1
Metabolic 17 10
•	 Electrolytic disorders 13 8
•	 Metabolic acidosis, ketoacidosis coma, 
hypoglycemia, and decompensated diabetes
4 2
Renal disease 14 8
•	 Acute renal failure 14 8
Infectious disease 14 8
•	 Sepsis 12 7
•	 Erysipelas 1 <1
•	 Fever of unknown origin 1 <1
Digestive 9 5
•	 Hepatic failure 4 2
•	 Hemorrhage 3 2
•	 Abdominal compartment syndrome 2 1
Hemodynamics 9 5
•	 Septic shock 6 3
•	 Anaphylaxis 2 1
•	 Hemorrhagic shock 1 <1
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variables were significantly associated with hospital mortality 
in univariate analysis: metastatic disease, cancer phase at ICU 
admission, cancer status, causes of admissions, FiO2, SAPS II and 
SOFA scores, lactate, GOT, GPT, and CRP levels; in addition to 
those, we added in the multivariate model, the variables with a 
p-value <0.2: SpO2, PAL hemoglobin level, lymphocytes count, 
and ICU limitations <24 h.
In multivariate analysis, we found three statistically independ-
ent predictors of death during hospitalization: SOFA score (OR 
1.36 per one-unit increase, 95% CI: 1.15–1.60; p < 0.001), and GPT 
above the median value (OR 3.7, 95% CI: 1.52–9.03, p = 0.004) as 
predictive factors of poor outcome, while cardiovascular disease 
as cause of the admission (OR 0.23, 95% CI: 0.06–0.86, p = 0.03) 
being a predictive factor of better outcome (Table 5).
During the study period, 115 patients were discharged 
from the hospital. Median survival after hospital discharge was 
12.8  months (95% CI: 8.2–20.7). Table  6 shows the results of 
the univariate analyses for prognostic factors for survival after 
hospital discharge. The following variables were significantly 
associated with survival in univariate analyses: metastatic 
disease, cancer phase at ICU admission, cancer status, GOT, 
PAL, hemoglobin and lactate dehydrogenase (LDH) levels, 
SAPSII and Charlson scores, ICU life support limitations <24 h; 
in addition to those, we added in the multivariate model the 
variables with a p-value <0.2: Fi O2, GPT, and CRP levels, SOFA 
score, lymphocytes count. In multivariate analysis (Table  7), 
we found four statistically independent prognostic factors for 
survival after hospital discharge: metastatic disease (HR 7.9, 
95% CI:3.69–16.9, p < 0.001), GOT above the median value (HR 
3.22 95% CI:1.93–5.36, p < 0.001), SAPS score above the median 
value (HR 1.95 95% CI:1.21–3.16, p = 0.006), and ICU life sup-
port limitations at or during the first 24 h of ICU admission (HR 
8.52 CI 95%:3.66–19.87, p < 0.001).
DiscUssiOn
Eighteen percent of unplanned ICU admissions for an acute 
complication in an academic cancer hospital concerned patients 
with breast cancer, mainly for cardiovascular and respira-
tory diseases. The mortality rates in the ICU and during the 
hospital stay were 15 and 28%, and the median survival after 
discharge from the hospital was 12.8  months. Independent 
predictors of mortality during hospitalization were related 
to the acute complications: SOFA score and high GPT value 
and cardiovascular-related. After discharge from the hospital, 
independent prognostic factors for survival were more related to 
the cancer characteristics: metastatic disease, high GOT value, 
SAPS II score, and ICU life support limitations during the first 
24 h after admission.
Breast cancer is the leading cause of cancer in women. One 
among seven women will present during their life this poten-
tially devastating cancer. New therapies, including aggressive 
chemotherapy for localized operable cancer and for metastatic 
diseases, led to a significant improvement in survival and cure 
rates. Even for metastatic breast cancers that are unlikely to be 
cured, survival can reach many years. Whatever considering 
direct cancer complications or acute and delayed adverse events 
linked to its treatment, women with breast cancer are likely to 
be admitted during their lifetime in an ICU. We are confirming 
the importance of this problem in our series with 18% of the 
ICU admission occurring in patients with breast cancer.
TaBle 4 | Univariate analysis for hospital mortality of breast cancer patients admitted in the icU (N = 159).
all patients 
(N: 159)
alive at the end of 
the hospitalization 
(N: 115)
Died in the icU or at the  
end of the hospitalization 
(N: 44)
p-value
Age, median ± SD 58.5 ± 13.7 58.1 ± 13.7 59.6 ± 13.5 0.54
Metastatic disease
No 39 (25%) 35 (30%) 4 (9%) 0.003
Yes 120 (75%) 80 (70%) 40 (91%)
Cancer phase at ICU admission 0.008*
Diagnosis 4 (3%) 1 (<1%) 3 (7%) 0.06
Curative 40 (25%) 35 (30%) 5 (11%) 0.01
Control 97 (61%) 69 (60%) 28 (64%) 0.67
Pivot 17 (11%) 9 (8%) 8 (18%) 0.08
Palliative 1 (<1%) 1 (<1%) – 1
Cancer status 0.048*
Induction 15 (9%) 11 (10%) 4 (9%) 1
Complete remission 25 (16%) 22 (19%) 3 (7%) 0.09
Partial remission 1 (<1%) 1 (<1%) – 1
Stable 27 (17%) 23 (20%) 4 (9%) 0.16
Progression 91 (57%) 58 (50%) 33 (75%) 0.007
Causes of admissions 0.002*
Respiratory 28 (18%) 19 (17%) 9 (20%) 0.56
Cardiovascular 42 (26%) 38 (33%) 4 (9%) 0.002
Neurologic 31 (20%) 21 (18%) 10 (23%) 0.51
Digestive 8 (5%) 2 (2%) 6 (14%) 0.006
Infectious 13 (8%) 9 (8%) 4 (9%) 0.75
Hemodynamic 9 (6%) 5 (4%) 4 (9%) 0.26
Metabolic 16 (10%) 14 (12%) 2 (5%) 0.24
Renal disease 12 (8%) 7 (6%) 5 (11%) 0.32
Antineoplastic therapy within  
30 days before ICU admission
No 92 (58%) 66 (57%) 26 (59%) 0.85
Yes 67 (42%) 49 (43%) 18 (41%)
Vital parameters
Sp O2
N 156 112 44 0.18
Median (min–max) 95 (33–100) 95 (33–100) 94 (76–100)
Fi O2
N 156 112 44 <0.001
Median (min–Q1–Q3–max) 21 (21–21–21–100) 21 (21–21–21–80) 21 (21–21–30–100)
Lactate
N 54 27 0.002
Median (min–max) 8118 (6–139) 15 (6–89) 25 (12–139)
GOT
N 148 109 39
Median (IU/l) (min–max) 36 (8–1776) 29 (8–1776) 84 (15–1539) <0.001
GPT
N 148 109 39
Median (IU/l) (min–max) 24 (5–2130) 21 (5–275) 48 (9–2130) <0.001
PAL
N 147 108 39
Median (IU/l) (min–max) 231 (35–3319) 213 (36–2442) 272 (35–3319) 0.14
LDH
N 100 76 24
Median (IU/l) (min–max) 489 (164–29999) 481 (164–29999) 560 (266–23913) 0.23
Hemoglobin
N 157 113 44
Median (g/dl) (min–max) 11.9 (5.2–18.3) 11.9 (6.5–18.3) 10.9 (5.2–15.1) 0.08
Neutrophils
N 134 101 33
Median/μl (min–max) 5655 (120–37410) 5590 (540–37410) 6080 (120–23490) 0.31
(Continued)
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TaBle 5 | Multivariate analysis for hospital mortality of breast cancer 
patients admitted in the icU.
Odd ratio 95%ci p-value
SOFA score 1.36 1.15–1.60 <0.001
GPT > 24 (median) 3.7 1.52–9.03 0.004
Cardiovascular admissions 0.23 0.06–0.86 0.03
all patients 
(N: 159)
alive at the end of 
the hospitalization 
(N: 115)
Died in the icU or at the  
end of the hospitalization 
(N: 44)
p-value
Lymphocytes
N 129 99 30
Median/μl (min–max) 960 (100–13800) 1000 (100–13800) 735 (190–3910) 0.17
CRP
N 153 111 42
Median (mg/l) (min–max) 37.6 (0.2–413) 27.1 (0.3–325.4) 97.5 (0.2–413) <0.001
Charlson’s score
N 156 114 42
Median (min–max) 8 (3–15) 8 (3–15) 8 (5–14) 0.4
SAPS II score
N 154 111 43
Median (min–max) 35 (13–81) 33 (13–66) 43 (18–81) <0.001
SOFA score
N 155 111 44
Median (min–max) 2 (0–11) 1 (0–10) 4 (0–11) <0.001
ICU limitations (<24 h)
No 140 (89%) 104 (91%) 36 (84%) 0.25
Yes 17 (11%) 10 (9%) 7 (16%)
Missing data 2
*In categorical variables with more than two categories, we performed an overall test to assess whether there was an association between the categorical variable (considering all 
categories) and the outcome: first p-value. And then we tested each category vs. all others: p-value for each category.
p < 0.2 are in bold.
TaBle 4 | continued
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When admitting cancer patients into an ICU, there is a need 
for discussion between the intensivist, according to the prognosis 
of the acute complication, and the oncologist taking into account 
the therapeutic option that could be delivered during or after the 
ICU stay. However, few data are available on that important topic 
that can affect both cancer center and general hospitals. To the 
best of our knowledge, our study is the first large series specifi-
cally dealing with breast cancer patients admitted in an ICU.
A systematic review of the literature (8) evaluated the survival 
of patients with solid tumors admitted to ICU. It identified 25,339 
admissions between 1997 and 2011. Eight publications do not 
specify the types of solid tumors. Publications specifying the 
type of tumor identified altogether 8225 patients including 221 
with breast cancer (3%). The limited number of breast cancer 
patients at the difference of the present series could be linked to 
a selection bias as only a minority of ICU was from oncological 
centers. The only study comparable to our series, dealing only 
with breast cancer patients, find as main causes of admission: res-
piratory failure (29%), pericardial effusion, and arrhythmias (6%) 
(5). Other publications on mixed cancer populations included 
small samples of patients with breast cancer. No specific data 
for these breast cancer patients can be derived except the same 
type of complications leading to ICU admission were observed: 
respiratory failure and sepsis being the leading cause of admis-
sion (1, 2, 6, 9). The high rates of cardiovascular complications 
in our series may be explained by the cardiotoxic effect of some 
drugs used to treat breast cancer as anthracyclines derivatives 
and trastuzumab that are more commonly used today for (neo)
adjuvant chemotherapy than in the period considered in the 
Headley’s series (5). Effectively, five cases of cardiac failure linked 
to chemotherapy (anthracyclines, taxanes, and ciplatin-5FU), 
trastuzumab, and radiotherapy were recorded. The taxanes were 
implicated in the development of two cases of arrhythmia and 
aromatase inhibitors in three cases of thromboembolism.
In the systematic review previously mentioned (8), ICU 
mortality for all solid tumors ranged from 4.5 to 85%, hospital 
mortality from 4.6 to 77%, and 1-year mortality from 36 to 88%. 
A study combining gynecological and breast cancer patients 
found an ICU mortality of 31% and 6-month mortality of 68% 
(6). It is difficult to make a meaningful comparison due to the dif-
ferent case-mixes and the different definition of 1-year mortality 
or survival after hospital discharge. In our series, we observed a 
lower mortality rate. One explanation could be a kind of patient 
selection because in our institution, according to the cancer 
evolution and the patient’s wishes, decision for ICU life support 
limitations are taken before any ICU admission. Very few patients 
were admitted at pivotal or palliative phases, variables, which were 
not taken into account in the previous publications. Supporting 
this argument, we found that ICU life support limitations deci-
sion taken early in the course of the ICU stay was associated with 
a poor outcome. Those decisions were mainly taken in front of 
cancer evolution discovered after ICU admission.
Life support techniques used during the ICU stay, invasive 
mechanical ventilation, amines support, and cardiopulmonary 
TaBle 7 | Multivariate analysis for mortality to hospital discharge of 
breast cancer patients admitted in the icU.
hazard 
ratio
95% ci p-value
Metastatic extension (yes vs. no) 7.90 3.69–16.92 <0.0001
GOT > 36 (vs. ≤36) 3.22 1.93–5.36 <0.0001
SAPS > 35 (vs. ≤35) 1.95 1.21–3.16 0.0062
Life support limitations <24 h (yes vs. no) 8.52 3.66–19.87 <0.0001
TaBle 6 | Univariate analysis for survival after discharge (N = 115).
hazard ratio (95% ci) p-value
Age >58 vs. ≤58 1.05 (0.67–1.64) 0.84
Metastatic extension Yes vs. no 8.31 (3.94–17.51) <0.001
Phase of cancera Curative vs. other than curative 0.16 (0.08–0.31) <0.001
Control vs. other than control 3.43 (2.01–5.87) <0.001
Pivotal vs. other than pivotal 4.11 (2.02–8.35) <0.001
Status of cancerb Induction vs. other than induction 0.21 (0.07–0.67) 0.009
Remission vs. other than remission 0.38 (0.18–0.78) 0.009
Stable vs. other than stable 0.92 (0.54–1.57) 0.77
Progression vs. other than progression 3.47 (2.16–5.56) <0.001
Causes of admissionc Respiratory vs. other than respiratory 1.17 (0.67–2.06) 0.59
Cardiovascular vs. other than cardiovascular 0.47 (0.28–0.79) 0.004
Neurological vs. other than neurological 1.17 (0.65–2.09) 0.6
Infectious vs. other than infectious 0.45 (0.16–1.23) 0.12
Hemodynamic vs. other than hemodynamic 1.35 (0.49–3.71) 0.56
Metabolic vs. other than metabolic 1.98 (1.09–3.62) 0.03
Renal vs. other than renal 5.87 (2.42–14.23) <0.001
Antineoplastic treatment Yes vs. no 1.04 (0.66–1.63) 0.87
Sp O2% >95 vs. ≤95 0.95 (0.60–1.50) 0.82
Fl O2% >21 vs. 21 1.52 (0.87–2.66) 0.14
Lactate (mg/dl) >18 vs. ≤18 0.78 (0.39–1.48) 0.42
GOT IU/l >36 vs. ≤36 2.40 (1.52–3.81) <0.001
GPT IU/l >24 vs. ≤24 1.47 (0.93–2.34) 0.1
PAL IU/l >231 vs. ≤231 1.90 (1.20–3.00) 0.007
LDH IU/l >489 vs. ≤489 1.94 (1.09–3.46) 0.03
Hemoglobin (g/dl) >11.9 vs. ≤11.9 0.49 (0.31–0.77) 0.002
Neutrophils/μl >5655 vs. ≤5655 0.82 (0.51–1.34) 0.43
Lymphocytes/μl >960 vs. ≤960 0.64 (0.40–1.04) 0.07
CRP (mg/l) >37.6 vs. ≤37.6 1.50 (0.95–2.36) 0.08
Charlson’s score >8 vs. ≤8 1.98 (1.26–3.11) 0.003
SAPSII score >35 vs. ≤35 1.66 (1.05–2.62) 0.03
SOFA score >2 vs. ≤2 1.55 (0.97–2.47) 0.07
ICU life support techniques limitation <24 h Yes vs. no 7.32 (3.38–15.87) <0.001
aInsufficient cases to assess diagnostic and palliative phases.
bInsufficient number of cases to assess partial remission.
cInsufficient cases to assess the digestive admissions.
p < 0.2 are in bold.
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resuscitation, were associated with a higher mortality rate as 
in other publications (9, 10). We decided to not include them 
in the predictive and prognostic factors analyses because we 
only considered variables available at ICU admission except for 
gravity scores. In various publications, the prognosis in ICU 
and hospital stay of cancer patients is mainly influenced by the 
physiological disturbances caused by the complications leading 
to ICU admission (11–13). For breast cancer in particular, a 
relationship between hospital mortality and APACHE II score 
was reported (5) despite limited sensitivity (54%) for hospital 
mortality. We confirmed in this study that general ICU gravity 
scores, reflecting the importance of physiological disturbances, 
are predicting hospital mortality but are also of prognostic value 
for survival after hospital discharge. In addition, we identified 
some easily measurable variables like GPT as predictor of 
hospital mortality and GOT as prognostic factor for survival 
after hospital discharge. As the literature is scarce concerning 
the prognostic value of GOT/GPT in cancer patients admitted 
into ICU, we postulate that an increase in liver enzymes occurred 
in the context of multiple organ failure, secondary to the acute 
complication but can also be, in a limited number of patients, 
due to liver dysfunction in the context of metastasis in the liver, 
yet already present beforehand for some people. This relation-
ship had already been observed in a previous study on colorectal 
cancer from our group (13).
We confirmed the findings from previous publications that 
cancer characteristics retained their prognostic value for sur-
vival after hospital discharge, identifying in the present study 
metastatic disease as an independent prognostic factor. Indeed, 
a relationship was reported between the metastatic cancer extent 
and the hospital mortality (3, 10, 14).
Some limitations of our work have to be reported. The retro-
spective nature of the study could be associated with a selection 
bias. Nevertheless, all patients consecutively admitted to the ICU 
were recorded and all medical charts were available at time of the 
study, and only a few data were missing.
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This a single-center study carried out in a dedicated Belgian 
cancer center recruiting a large number of patients with breast 
cancer. This raises the question of the generalizability of our results. 
It would be interesting to conduct a prospective multicenter study 
with a larger number of patients and including oncological and 
general ICUs as well for confirming our data.
cOnclUsiOn
This is, to our knowledge, the first large sample-size study 
assessing unplanned ICU admission of patients with breast 
cancer. The ICU mortality was 15%, and the overall mortality 
of the patients during hospitalization was 28%. The prognostic 
factors for mortality during hospitalization were related to the 
acute complications leading to critical care: SOFA score, GPT 
level, and cardiovascular-related admission. The prognostic 
factors of mortality after hospitalization were more related to 
the cancer characteristics: metastatic disease, GOT level, SAPS 
score, and therapeutic limitations during the first 24  h after 
admission.
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